-
Coumestrol Drives PMAIP1-Linked Ferroptosis in RA
2026-09-21
A 2026 study identifies a TRIM3–PMAIP1 protein-stability axis through which Coumestrol promotes ferroptosis in rheumatoid arthritis fibroblast-like synoviocytes. The findings connect mitochondrial stress, iron accumulation, inflammatory cytokine production, and synoviocyte proliferation, while also highlighting the need to distinguish this mechanism from Coumestrol’s established nuclear receptor activity.
-
Resiniferatoxin: From TRPV1 Biology to Translation
2026-09-21
Resiniferatoxin (RTX) is more than an ultra-potent TRPV1 agonist: it is a mechanistic tool for testing how selective sensory-neuron activation becomes durable functional silencing. This article connects RTX biology with GERD pathway research, pain-model design, route selection, and translational decision-making.
-
Machine Learning for Senolytic Discovery
2026-09-20
The reference study shows that cost-effective machine-learning models trained on published, heterogeneous data can identify candidate senolytics without requiring a large new screening campaign. Experimental validation of ginkgetin, periplocin, and oleandrin illustrates how computational prioritization can reduce discovery costs while exposing important questions about selectivity, potency, and transferability across senescent cell models.
-
Z-DEVD-FMK: Caspase-3 Inhibitor Guide
2026-09-19
Z-DEVD-FMK is a cell-permeable, irreversible caspase-3 inhibitor that also affects caspases-6, -7, -8, -10, and calpain-mediated proteolysis. Its reported use spans apoptosis assays and traumatic brain injury neuroprotection, but it is not a selective probe for caspase-1-dependent pyroptosis.
-
Alda 1: A Practical ALDH2 Activator Workflow
2026-09-19
Alda 1 enables genotype-aware studies of aldehyde detoxification, cardioprotection in ischemia, and cardiomyocyte proliferation. This guide converts its ALDH2 activation profile into assay-ready workflows, controls, and troubleshooting strategies for cardiac and radiation injury research.
-
Bortezomib (PS-341): Reversible Proteasome Inhibitor
2026-09-18
Bortezomib, also called PS-341, is a reversible 20S proteasome inhibitor used to study proteostasis, apoptosis, multiple myeloma research, and mantle cell lymphoma research. Product and literature evidence support its use as a mechanistic research tool, while assay-specific potency, solubility, storage, and in vivo exposure require condition-matched interpretation.
-
Fosinopril sodium in Cardiovascular Research
2026-09-17
Fosinopril sodium connects zinc-targeted ACE inhibition with measurable blood pressure, cardiac, and renal phenotypes. This guide translates its prodrug chemistry into reproducible assay workflows, while adapting the endpoint discipline of a major cardiovascular outcomes trial for preclinical hypertension research.
-
Intra-articular RTX for Osteoarthritic Pain
2026-09-17
The 2025 review evaluates intra-articular resiniferatoxin (RTX) as a localized TRPV1-targeting strategy for osteoarthritic pain. Its central insight is that sustained TRPV1 activation can produce selective chemical silencing of peripheral nociceptive terminals, while the evidence base remains predominantly preclinical with early human data reported mainly in abstract form.
-
Prostaglandin E2: Mechanism and Research Use
2026-09-17
Prostaglandin E2 (PGE2) is an endogenous lipid-derived autacoid that activates four EP receptor subtypes with distinct binding affinities. This article connects receptor pharmacology, inflammation research, gastrointestinal mucosal protection, immune regulation, and practical handling of B7005 while separating direct PGE2 evidence from related arachidonic-acid findings.
-
E-4031 for 3D Cardiac Electrophysiology
2026-09-16
E-4031 provides a defined pharmacological challenge for hERG/IKr-dependent repolarization studies, from organoid shell-MEA mapping to action-potential analysis. This guide translates the reference study into practical dosing, recording, troubleshooting, and interpretation strategies for cardiac electrophysiology research.
-
Obeticholic Acid FXR Workflows for Liver Research
2026-09-15
Build receptor-proximal assays with Obeticholic Acid to connect FXR activation with bile acid transport, cholestasis, and fibrosis-relevant phenotypes. The workflow also shows how to compare FXR readouts with the Notch and natural-killer-cell findings from a recent liver fibrosis study without conflating distinct mechanisms.
-
LNP-miR-200c Suppresses Pancreatic Cancer Progression
2026-09-15
Yu et al. show that miR-200c functions through two separable regulatory routes in pancreatic cancer: nuclear activation of PTPN6 through an enhancer and post-transcriptional repression of CDH17. LNP-mediated delivery reproduced the antitumor effect in vivo, providing a mechanistic rationale for studying miRNA localization, enhancer regulation, and delivery together.
-
Recombinant Mouse M-CSF for Causal Assays
2026-09-14
Recombinant Mouse Macrophage Colony Stimulating Factor (M-CSF) is more than a differentiation reagent: it is a critical variable in macrophage assay design. This article connects PM2021 specifications with the IGF2BP1–THBS1–TLR4 fibrosis mechanism to improve causal interpretation, controls, and workflow selection.
-
SPI1–Wnt5a Signaling in Intracranial Aneurysm
2026-09-14
A 2026 study identifies SPI1 as a transcriptional regulator that promotes intracranial aneurysm formation by suppressing Wnt5a and activating canonical Wnt/β-catenin signaling. Its combined cell, chromatin, and mouse-model evidence links this axis to vascular smooth muscle cell phenotypic switching, arterial wall injury, and inflammation.
-
Necrosome Assembly and RIP3 Stoichiometry
2026-09-13
This study combines quantitative STORM imaging with mathematical modeling to identify an approximately 3:1 RIP3:RIP1 stoichiometry that optimizes necrosome-driven necroptosis. It also shows that excessive RIP3 oligomerization attenuates signaling, revealing how signalosome size and composition jointly balance amplification with response control.